Status:
COMPLETED
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Progressive Multifocal Leukoencephalopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Progressive multifocal leukoencephalopathy (PML) is a rare viral infection of the central nervous system (CNS) occurring in immunocompromised patients. Recovery of JC virus (JCV) specific T cell immun...
Detailed Description
PML is a devastating orphan disease of the CNS due to the reactivation of JCV in immunocompromised patients. Given the lack of drugs controlling JCV replication, initiation of antiretroviral therapy i...
Eligibility Criteria
Inclusion
- Adults ≥18 years old
- Informed consent
- Active virological PML : Recent neurological symptoms (\< 3 months) with brain MRI lesions suggestive of PML and positive PCR in cerebrospinal fluid for JCV
- Affiliated or benefiting from public health insurance.
Exclusion
- Non active PML
- Possible PML with negative JCV PCR
- Adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision
- Pregnant and/or breastfeeding women
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 12 2024
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04453917
Start Date
February 23 2021
End Date
July 12 2024
Last Update
December 31 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Bordeaux
Bordeaux, France
2
CHU Montpellier
Montpellier, France
3
CHU de TOULOUSE
Toulouse, France, 31000